{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:46:18Z","timestamp":1757450778001},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Considering the considerable prevalence of allergic disease in the general population, an urgent need exists for inactivated SARS-CoV-2 vaccines that can be safely administered to those subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study including 1926 participants who received inactivated SARS-CoV-2 vaccines, compared their local and systemic reactions in 7\u00a0days after each dose of inactivated SARS-CoV-2 vaccine, and anti\u2013SARS-CoV-2 IgG after vaccination in all participants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Pain at the injection site within seven days after the first injection was the most commonly reported local reaction, occurring in 31.0% of the patients with allergic disease and 18.9% in the control group, respectively (P\u2009&lt;\u20090.001). After the first dose, systemic events were more frequently reported in patients with allergic disease than control group (30.2% vs. 22.9%, P\u2009&lt;\u20090.001). After the second dose, systemic events occurred less often, affecting 17.1% of the patients with allergic disease and 11.1% of the control group (P\u2009&lt;\u20090.002). The occurrence of fatigue, vertigo, diarrhea, skin rash, sore throat were the most frequent systemic reactions. Overall, a lower incidence of local and systemic reactive events was observed after the second dose than the first dose in patients with allergic disease and control group. Nearly all participants had positive IgG antibodies, and participants with allergic disease had higher frequencies compared with control group (100.0 vs.99.4%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although local and systemic reactions were more frequently reported in patients with allergic disease than control group, administration of the inactivated SARS-CoV-2 vaccine was safe and well tolerated by all participants; no participants experienced a serious adverse event, and none were hospitalized.<\/jats:p>\n                <jats:p><jats:italic>Trial registration:<\/jats:italic> Chinese Clinical Trial Registry, ChiCTR2100048549. Registered Jul 10, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02054-1","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T15:02:59Z","timestamp":1653663779000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"chictr2100048549","registry":"10.18810\/chictr"}],"author":[{"given":"Chao","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liemin","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"2054_CR1","unstructured":"WHO coronavirus (COVID-19) dashboard (2021). https:\/\/covid19.who.int\/."},{"key":"2054_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck Jr","year":"2021","unstructured":"Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239\u201350.","journal-title":"N Engl J Med"},{"key":"2054_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01469-5","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021. https:\/\/doi.org\/10.1038\/s41591-021-01469-5.","journal-title":"Nat Med"},{"key":"2054_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21:39\u201351.","journal-title":"Lancet Infect Dis"},{"key":"2054_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","author":"S Wu","year":"2021","unstructured":"Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(20)31208-3.","journal-title":"Lancet Infect Dis"},{"key":"2054_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021;384:2187\u2013201.","journal-title":"N Engl J Med"},{"key":"2054_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13223-021-00529-2","volume":"17","author":"TK Vander Leek","year":"2021","unstructured":"Vander Leek TK, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JEM, Abrams EM. COVID-19 vaccine testing & administration guidance for allergists\/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17:29.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2054_CR8","unstructured":"Justiz Vaillant AA, Vashisht R, Zito PM: Immediate Hypersensitivity Reactions. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2021, StatPearls Publishing LLC.; 2021"},{"key":"2054_CR9","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/all.14582","volume":"75","author":"H Breiteneder","year":"2020","unstructured":"Breiteneder H, Peng YQ. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75:3039\u201368.","journal-title":"Allergy"},{"key":"2054_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fimmu.2019.00175","volume":"10","author":"G Gomez","year":"2019","unstructured":"Gomez G. Current strategies to inhibit high affinity Fc\u03b5RI-mediated signaling for the treatment of allergic disease. Front Immunol. 2019;10:175.","journal-title":"Front Immunol"},{"key":"2054_CR11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/exd.13769","volume":"27","author":"S Gilles","year":"2018","unstructured":"Gilles S, Akdis C, Lauener R, Schmid-Grendelmeier P, Bieber T, Sch\u00e4ppi G, Traidl-Hoffmann C. The role of environmental factors in allergy: A critical reappraisal. Exp Dermatol. 2018;27:1193\u2013200.","journal-title":"Exp Dermatol"},{"key":"2054_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/all.15077","author":"N Mitselou","year":"2021","unstructured":"Mitselou N, Andersson N, Bergstr\u00f6m A, Kull I. Preterm birth reduces the risk of IgE sensitization up to early adulthood: a population-based birth cohort study. Allergy. 2021. https:\/\/doi.org\/10.1111\/all.15077.","journal-title":"Allergy"},{"key":"2054_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.06.022","author":"SC Morris","year":"2021","unstructured":"Morris SC, Perkins C, Potter C, Parsons D, Schuman R, Khodoun MV, Samavedam U, Strait R, Finkelman FD. Optimizing drug inhibition of IgE-mediated anaphylaxis in mice. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.06.022.","journal-title":"J Allergy Clin Immunol"},{"key":"2054_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.050","author":"LF Pennington","year":"2021","unstructured":"Pennington LF, Gasser P, Brigger D, Guntern P, Eggel A, Jardetzky TS. Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.03.050.","journal-title":"J Allergy Clin Immunol"},{"key":"2054_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/all.14843","author":"A Goretzki","year":"2021","unstructured":"Goretzki A, Lin YJ, Sch\u00fclke S. Immune metabolism in allergies, does it matter?-A review of immune metabolic basics and adaptations associated with the activation of innate immune cells in allergy. Allergy. 2021. https:\/\/doi.org\/10.1111\/all.14843.","journal-title":"Allergy"},{"key":"2054_CR16","unstructured":"Administration UFaD: Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rocakville: Center for Biologics Evaluation and Research; 2007."},{"key":"2054_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/0004563220963847","volume":"57","author":"Y Wan","year":"2020","unstructured":"Wan Y, Li Z, Wang K, Li T, Liao P. Performance verification of anti-SARS-CoV-2-specific antibody detection by using four chemiluminescence immunoassay systems. Ann Clin Biochem. 2020;57:429\u201334.","journal-title":"Ann Clin Biochem"},{"key":"2054_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.704773","volume":"12","author":"E Zitt","year":"2021","unstructured":"Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, Benda MA, Sprenger-M\u00e4hr H, Winder T, Lhotta K. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Front Immunol. 2021;12: 704773.","journal-title":"Front Immunol"},{"key":"2054_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijid.2021.07.063","volume":"110","author":"T Perkmann","year":"2021","unstructured":"Perkmann T, Perkmann-Nagele N, Mucher P, Radakovics A, Repl M, Koller T, Jordakieva G, Wagner OF, Binder CJ, Haslacher H. Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222. Int J Infect Dis. 2021;110:309\u201313.","journal-title":"Int J Infect Dis"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02054-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T15:10:34Z","timestamp":1653664234000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02054-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02054-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Commission of Ningbo First Hospital and written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest in relation to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}